Skip to content
Select your cancer type
▼
  • ESCC
  • GC/GEJC
  • NSCLC
Indication:
▼
  • 1 L ESCC
  • 1 L GC/GEJC
  • 2 L ESCC
  • Non-Squamous NSCLC
  • Squamous NSCLC

Language

This site is inteded for health care proffesional.

Significant improvement in overall survival seen in the all-comer population of 2L NSCLC and PD-L1 scores ≥1%1

Subgroup analysis of overall survival in the intent-to-treat population

Etapidi had a marked improved and long term clinical benefit in patients with locally advanced or metastatic NSCLC who progressed on or after platinum-based chemotherapy, regardless of tumor PD-L1 expression or pathologic type

OS in the ITT population1

Co-primary endpoints: OS in ITT

Etapidi met the OS primary endpoint with significantly prolonged median OS versus docetaxel by 42% 

OS in the PD-L1 ≥ 25% population1

Co-primary endpoints: PD-L1 ≥25% populations

In the PD-L1 ≥ 25% population, Etapidi had a statistically significant and clinically meaningful OS benefit versus docetaxel 1

Explore ORR, mDoR, and mPFS in patients with Squamous NSCLC

Data cut off : July 15, 2021.
Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial

References: 1. Zhou, Caicun et al. Journal of Thoracic Oncology, 2023, Volume 18, Issue 1, 93 – 105. 2. Tislelizumab Versus Docetaxel in Patients with Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial Zhou, Caicun et al. Journal of Thoracic Oncology, 2022, Volume 18, Issue 1, 93 – 105. 3.Zhou, Caicun et al. Journal of Thoracic Oncology, 2023, Volume 18, Issue 1, 93 – 106